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BACKGROUND: CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell car-
cinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab versus 
everolimus. METHODS: The randomized, open-label, phase 3 CheckMate 025 trial (NCT01668784) included patients with clear cell aRCC 
previously treated with 1 or 2 antiangiogenic regimens. Patients were randomized to nivolumab (3 mg/kg every 2 weeks) or everolimus 
(10 mg once a day) until progression or unacceptable toxicity. The primary endpoint was overall survival (OS). The secondary endpoints 
were the confirmed objective response rate (ORR), progression-free survival (PFS), safety, and health-related quality of life (HRQOL). 
RESULTS: Eight hundred twenty-one patients were randomized to nivolumab (n  = 410) or everolimus (n  = 411); 803 patients were 
treated (406 with nivolumab and 397 with everolimus). With a minimum follow-up of 64 months (median, 72 months), nivolumab main-
tained an OS benefit in comparison with everolimus (median, 25.8 months [95% CI, 22.2-29.8 months] vs 19.7 months [95% CI, 17.6-22.1 
months]; hazard ratio [HR], 0.73; 95% CI, 0.62-0.85) with 5-year OS probabilities of 26% and 18%, respectively. ORR was higher with 
nivolumab (94 of 410 [23%] vs 17 of 411 [4%]; P < .001). PFS also favored nivolumab (HR, 0.84; 95% CI, 0.72-0.99; P = .0331). The most 
common treatment-related adverse events of any grade were fatigue (34.7%) and pruritus (15.5%) with nivolumab and fatigue (34.5%) 
and stomatitis (29.5%) with everolimus. HRQOL improved from baseline with nivolumab but remained the same or deteriorated with  
everolimus. CONCLUSIONS: The superior efficacy of nivolumab over everolimus is maintained after extended follow-up with no  
new safety signals, and this supports the long-term benefits of nivolumab monotherapy in patients with previously treated aRCC.  
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LAY SUMMARY: 
• CheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with those of everolimus (an older standard-of-care 
therapy) for the treatment of advanced kidney cancer in patients who had progressed on antiangiogenic therapy.
• After 5 years of study, nivolumab continues to be better than everolimus in extending the lives of patients, providing a long-lasting 
response to treatment, and improving quality of life with a manageable safety profile. The results demonstrate that the clinical benefits 
of nivolumab versus everolimus in previously treated patients with advanced kidney cancer continue in the long term. 
KEYWORDS: advanced renal cell carcinoma (aRCC), CheckMate 025, everolimus, immune checkpoint inhibitor, nivolumab, previously 
treated.
INTRODUCTION
Nivolumab, a fully human immunoglobulin G4 PD-1 
immune checkpoint inhibitor, disrupts PD-L1–medi-
ated signaling to restore the immune system’s antitumor 
defenses.1-3 Nivolumab monotherapy has previously 
demonstrated antitumor activity associated with im-
proved overall survival (OS) in multiple malignancies, 
including advanced renal cell carcinoma (aRCC).1
The phase 3 CheckMate 025 trial compared 
nivolumab with everolimus, a mammalian target of rapa-
mycin inhibitor, in patients who had aRCC with a clear 
cell component and had previously been treated with 
antiangiogenic therapy (NCT01668784). After an in-
terim analysis performed with a minimum follow-up 
of 14 months, the trial was stopped early because of a 
demonstrated OS benefit with nivolumab over everolimus 
(hazard ratio [HR], 0.73; 95% confidence interval [CI], 
0.57-0.93; P = .002]); a survival benefit was observed with 
nivolumab, regardless of the tumor PD-L1 expression 
level.4 The objective response rate (ORR) per investigator 
was significantly improved with nivolumab versus evero-
limus (P <  .001), and although median progression-free 
survival (PFS) was similar between treatment arms, a de-
layed benefit with nivolumab was observed after 6 months 
of treatment.4 The confirmed investigator-assessed ORR 
was 21.5% (95% CI, 17.6%-25.8%) with nivolumab and 
3.9% (95% CI, 2.2%-6.2%) with everolimus.1 Beyond 
the observed clinical benefits, nivolumab was associated 
with improvements in patient-reported health-related 
quality of life (HRQOL) outcomes in comparison with 
everolimus.5 Long-term updates critically inform the ben-
efit/risk ratio of immunotherapeutic regimens. Here, we 
report an updated and expanded analysis with an extended 
minimum follow-up of 64 months for patients treated 
with nivolumab or everolimus in CheckMate 025.
MATERIALS AND METHODS
Study Design and Participants
The study methodology was previously reported in de-
tail.4 Briefly, CheckMate 025 was a randomized, open-
label, phase 3 trial conducted across 146 university- or 
hospital-based sites in 24 countries globally. Patients were 
18 years old or older, had histologically confirmed ad-
vanced or metastatic renal cell carcinoma (RCC) with a 
predominantly clear cell component, and had measurable 
disease according to the Response Evaluation Criteria in 
Solid Tumors, version 1.1 (RECIST v1.1). Eligible pa-
tients had previously received 1 or 2 antiangiogenic thera-
pies and had a Karnofsky performance status ≥ 70.
Randomization and Masking
Patients were randomly assigned (1:1) to nivolumab or 
everolimus through an interactive voice response sys-
tem. Randomization was performed via permuted blocks 
within each stratum, and stratified by Memorial Sloan 
Kettering Cancer Center risk group (favorable vs inter-
mediate vs poor), number of prior antiangiogenic thera-
pies in the advanced or metastatic setting (1 vs 2), and 
geographical region (United States/Canada vs Western 
Europe vs rest of the world). Patients and investigators 
were not masked to the treatment assignment because this 
was an open-label trial.
Study Oversight
The study was approved by an institutional review board 
or independent ethics committee at each center and was 
conducted in accordance with Good Clinical Practice 
guidelines, as defined by the International Conference for 
Harmonisation. All patients provided written informed 
consent based on the principles of the Declaration of 
Helsinki.
Procedures
Patients were randomized 1:1 to receive nivolumab (3 mg/kg 
intravenously every 2 weeks) or everolimus (10 mg/d 
orally) until disease progression, unacceptable toxicity, or 
withdrawal of consent. Patients were permitted to continue 
treatment beyond progression if a clinical benefit was iden-
tified by the investigator and the adverse event (AE) profile 
was acceptable. Dose reductions and escalations were per-
mitted for everolimus but not for nivolumab, whereas dose 
delays were permitted for both treatments. Tumor assess-
ments were performed at the baseline, every 8 weeks for 
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the first year, and then every 12 weeks until disease pro-
gression or discontinuation of treatment and were evalu-
ated by the investigator per RECIST v1.1. Crossover from 
everolimus to a nivolumab extension phase was allowed 
per a protocol amendment implemented after OS superi-
ority for patients receiving nivolumab was demonstrated 
in the primary analysis (July 2015). Patients treated with 
everolimus could be assessed for crossover to nivolumab if 
they met criteria for laboratory values and if all toxicities 
attributed to prior anticancer therapy, except for alopecia 
and fatigue, had resolved to grade 1 or the baseline before 
the initiation of nivolumab. A 14-day washout period for 
prior systemic anticancer therapy was required before the 
first nivolumab crossover dose.
AEs were graded according to the National Cancer 
Institute’s Common Terminology Criteria for Adverse 
Events, version 4.0.6 Select AEs were defined as AEs of spe-
cial clinical interest that may differ in type, frequency, or 
severity from AEs associated with nonimmunotherapies; 
these may require immunosuppression for their manage-
ment, and early recognition may mitigate severe toxicity. 
HRQOL was assessed with the Functional Assessment 
of Cancer Therapy Kidney Symptom Index–Disease-
Related Symptoms (FKSI-DRS) scoring algorithm.7
Outcomes
This prespecified follow-up analysis included the origi-
nal primary endpoint of OS together with the following 
secondary endpoints: confirmed ORR per investigator ac-
cording to RECIST v1.1, PFS per investigator according 
to RECIST v1.1, safety, and patient-reported HRQOL.4 
The effects of various baseline clinical features on OS 
were assessed post hoc by univariable and multivariable 
models in an exploratory analysis of both arms.
The treatment-free interval was defined as the time 
between protocol therapy discontinuation and subse-
quent systemic anticancer treatment initiation or the time 
between protocol therapy discontinuation and the date 
on which a patient was last known to be alive among pa-
tients who never received subsequent systemic anticancer 
treatment.
Treatment-related AEs were reported between the 
first dose and 30 days after the last dose of study therapy 
or at the beginning of the nivolumab extension phase, 
whichever came first. Treatment-related AEs that contin-
ued beyond this time point were followed to resolution 
or until they were deemed irreversible by the investigator. 
Treatment-related select AEs were reported between the 
first dose and 30 days after the last dose of study therapy 
for patients in the nivolumab arm and included events 
occurring in skin, gastrointestinal, endocrine, hepatic, 
pulmonary, or renal systems. Median times to the onset 
and resolution of treatment-related select AEs were re-
ported for patients in the nivolumab and everolimus arms.
Statistical Analysis
The Kaplan-Meier method was used to estimate the OS, 
PFS, duration of response, and time to resolution of select 
AEs.8 OS and PFS HRs for nivolumab versus everolimus 
were estimated with the Cox proportional hazards model9 
with the treatment group as a single covariate. ORRs and 
corresponding 95% CIs were calculated on the basis of 
the Clopper and Pearson method.10 A post hoc analysis of 
the effects of clinically relevant baseline features—tumor 
PD-L1 expression, neutrophil-to-lymphocyte ratio, me-
dian sum of reference diameters of target lesions, prior 
nephrectomy, and individual International Metastatic 
Renal Cell Carcinoma Database Consortium (IMDC) 
risk factors—on OS was performed with univariable and 
multivariable models sequentially for each intent-to-treat 
treatment arm separately to differentiate between factors 
relevant to nivolumab and everolimus. Each factor was 
first analyzed individually in the univariable analysis. 
Baseline factors associated with OS at P < .1 in the uni-
variable model were entered into a full Cox proportional 
hazards multivariable regression model. Backward regres-
sion was used to build a parsimonious (reduced) multi-
variable model that included all baseline factors associated 
with OS at P < .1. Descriptive statistics were used to as-
sess treatment-related AEs, the onset of select AEs, and 
changes from the baseline in HRQOL.
RESULTS
Patients
Between October 9, 2012, and March 14, 2014, 821 pa-
tients were randomized (410 into the nivolumab arm and 
411 into the everolimus arm), and 803 were treated (406 
in the nivolumab arm and 397 in the everolimus arm). 
Baseline characteristics have been previously reported and 
were balanced between arms (Supporting Table 1). The 
minimum follow-up was 64 months (median, 72 months). 
As of the August 2019 database lock, 100 patients (24.6%) 
randomized to the nivolumab arm were still alive, whereas 
65 patients (16.4%) initially randomized to everolimus 
were. Ten patients (2.5%) in the nivolumab arm and 2 
(0.5%) in the everolimus arm continued to receive treat-
ment. The primary reason for discontinuation in both 
arms was disease progression (78.1% in the nivolumab 
arm and 74.1% in the everolimus arm; Supporting Fig. 1).
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Sixty-five patients (16.4%) in the everolimus arm 
crossed over to the nivolumab extension. Patients who 
were eligible to cross over to the nivolumab extension 
phase were a highly select group of patients who pro-
gressed on everolimus therapy and were healthy enough 
to begin nivolumab treatment.
Efficacy
In all randomized patients, an OS benefit was maintained 
with nivolumab versus everolimus (HR, 0.73; 95% CI, 
0.62-0.85; P <  .0001; Fig. 1A). The 36-, 48-, and 60-
month OS probabilities with nivolumab and everolimus 
were 39% (95% CI, 34%-44%) and 30% (95% CI, 
25%-34%), 30% (95% CI, 25%-34%) and 23% (95% 
CI, 19%-27%), and 26% (95% CI, 21%-30%) and 18% 
(95% CI, 14%-22%), respectively.
PFS with nivolumab and everolimus was simi-
lar through 6 months, after which the Kaplan-Meier 
curves separated; nivolumab was favored with extended 
follow-up (HR, 0.84; 95% CI, 0.72-0.99; P  =  .0331; 
Fig. 1B). The 36-, 48-, and 60-month PFS probabili-
ties with nivolumab and everolimus were 9% (95% CI, 
6%-12%) and 2% (95% CI, 1%-4%), 6% (95% CI, 
4%-9%) and 1% (95% CI, 0%-3%), and 5% (95% 
CI, 3%-8%) and 1% (95% CI, 0%-3%), respectively.
ORR was 22.9% (95% CI, 18.9%-27.3%) with 
nivolumab and 4.1% (95% CI, 2.4%-6.5%) with evero-
limus (odds ratio, 6.86; 95% CI, 4.01-11.74; P < .0001; 
Table 1). A complete response was observed in 1.0% of 
the patients (n = 4) in the nivolumab group and in 0.5% 
of the patients (n = 2) in the everolimus group, whereas 
a partial response was seen in 22.0% of the nivolum-
ab-treated patients (n = 90) and in 3.6% of the everolim-
us-treated patients (n = 15).
The median time to a response was 3.5 months for 
nivolumab and 3.7 months for everolimus. The median 
duration of response was 18.2 months (95% CI, 12.9-
25.8 months) with nivolumab and 14.0 months (95% 
CI, 8.3-19.2 months) with everolimus (Fig. 2), with on-
going responses at the time of the database lock in 26 of 
94 nivolumab responders (27.7%) and in 3 of 17 evero-
limus responders (17.6%). For patients who had a com-
plete response with nivolumab (n = 4), the median time 
to a confirmed response for the complete responders was 
2.2 months, and the duration of response ranged from 
4.5 to 65.1+ months. Two of the 4 patients with com-
plete responses in the nivolumab arm had an ongoing 
response. Both patients were off treatment and did not 
receive subsequent therapy. For patients who had a com-
plete response with everolimus (n = 2), the median time 
to a confirmed response for the complete responders was 
4.6 months with durations of 8.3 and 13.7 months. For 
patients in the nivolumab arm with a partial response 
(n = 90), the median time to a confirmed response for 
the partial responders was 4.8 months with a median du-
ration of 18 months (95% CI, 12.9-25.1 months). For 
patients in the everolimus arm with a partial response 
(n = 15), the median time to a confirmed response for 
the partial responders was 3.5 months with a median 
duration of 17.9 months (95% CI, 6.4-24.0 months).
In the nivolumab arm, 59 responders (63%) received 
subsequent therapy, and 15 (88%) did in the everolimus 
arm; 8 responders (9%) in the nivolumab arm and 1 re-
sponder (6%) in the everolimus arm remained on therapy 
at the time of the database lock (Fig. 3). For all respond-
ers, the median duration of treatment was 23.6 months 
for nivolumab and 24.4 months for everolimus. For pa-
tients who responded and were off treatment without any 
subsequent systemic therapy, the median duration of the 
treatment-free interval was 12.7 months (interquartile 
range, 2.8-28.9 months) for nivolumab and 4.1 months 
(interquartile range, 4.1-4.1 months) for everolimus.
Patients Who Crossed Over to Nivolumab
As expected, more patients who crossed over had Memorial 
Sloan Kettering Cancer Center and IMDC favorable-risk 
disease and only 1 site of metastasis, and a lower proportion 
had prior radiotherapy, prior pazopanib treatment, liver 
and bone baseline tumor sites, and tumor PD-L1 expres-
sion ≥ 1% (Supporting Table 1).4 Seven patients (10.8%) 
who crossed over from everolimus to nivolumab contin-
ued to receive treatment at the time of the 5-year analysis. 
The primary reasons for discontinuation in patients who 
crossed over from everolimus to nivolumab were disease 
progression (69.2%) and toxicity with nivolumab (10.8%).
Among the 65 patients who crossed over to 
nivolumab, the 36-, 48-, and 60-month OS probabilities 
from initial study randomization were 89%, 71%, and 
59%, respectively (Supporting Fig. 2A). The PFS prob-
ability was 13% (95% CI, 6.0%-25.0%) at both 24 and 
36 months after crossover in this population (Supporting 
Fig. 2B). The ORR after crossover was 7.7% (95% CI, 
2.5%-17.0%), with 1.5% of patients (n = 1) achieving 
a complete response and 6.2% (n = 4) achieving a par-
tial response (Table 1). For patients who crossed over 
to nivolumab and had a confirmed response (n  =  5), 
the median time to a response after crossover was 1.9 
months with a median duration of 16.5 months (range, 
7.4-35.5+ months), and 2 of the 5 responders (40%) 
had an ongoing response at the time of the database lock.
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Impact of Baseline Clinical Features on OS: A 
Multivariable Model
A multivariable model was used to assess the impact 
of baseline clinical features on OS. Baseline factors 
were first analyzed individually in a univariable analy-
sis to preclude introducing collinearity into the model 
(Supporting Table 2). The exploratory univariable 
analysis did not show baseline tumor PD-L1 expression 
≥ 1% to be an independent prognostic factor for OS 
with either nivolumab or everolimus. Significant nega-
tive prognostic effects of lower hemoglobin levels and 
a higher tumor burden (sum of the reference diameters 
of target lesions) on OS were observed in the final re-
duced multivariable models in both the nivolumab and 
FIGURE 1. (A) OS and (B) PFS for patients treated with nivolumab and everolimus. CI indicates confidence interval; HR, hazard ratio; 
OS, overall survival; PFS, progression-free survival.
A
B
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everolimus arms (Supporting Table 3). A shorter time 
from the diagnosis of metastatic disease to the initiation 
of therapy was uniquely prognostic for shorter OS in 
the nivolumab arm. A higher corrected calcium level, 
a higher neutrophil-to-lymphocyte ratio, and the pres-
ence of bone metastases (with or without a soft-tissue 
component) were uniquely prognostic for shorter OS in 
the everolimus arm alone (Supporting Table 3).
Treatment Administration and Safety
In all treated patients, the overall incidence of treat-
ment-related AEs was 80.5% (grade 3 or 4, 21.4%) in 
the nivolumab group and 88.9% (grade 3 or 4, 36.8%) 
in the everolimus group. The most common treatment-
related AEs of any grade with nivolumab were fatigue 
(34.7%), pruritus (15.5%), nausea (15.0%), and diar-
rhea (13.8%; Fig. 4A). The most common treatment-
related AEs of any grade with everolimus were fatigue 
(34.5%), stomatitis (29.5%), and anemia (24.4%; 
Fig. 4A). The most common grade 3 or 4 treatment-
related AEs with nivolumab were fatigue (2.7%), ane-
mia (2.0%), increased alanine aminotransferase (1.7%), 
and increased aspartate aminotransferase (1.7%). The 
most common grade 3 or 4 treatment-related AEs 
with everolimus were anemia (8.6%), hypertriglyceri-
demia (4.5%), stomatitis (4.3%), and hyperglycemia 
(3.8%). Treatment-related AEs of any grade leading 
to discontinuation occurred in 39 patients (9.6%) in 
the nivolumab arm and in 50 patients (12.6%) in the 
everolimus arm. No additional treatment-related deaths 
were reported since the primary analysis in either arm 
(none in the nivolumab arm and 2 in the everolimus 
arm4). Among patients who crossed over from everoli-
mus to nivolumab, the median duration of nivolumab 
treatment was 8.8 months (95% CI, 6.5-11.4 months). 
Treatment-related AEs of any grade occurred in 83.1% 
TABLE 1. Best Overall Responses and Objective Response Rates
Nivolumab (n = 410) Everolimus (n = 411)
Crossover to 
Nivolumab (n = 65)
Objective response rate, No. (%) 94 (22.9) 17 (4.1) 5 (7.7)
95% CI 18.9-27.3 2.4-6.5 2.5-17.0
Odds ratio (95% CI) 6.86 (4.0-11.7) —
Best overall response, No. (%)
Complete response 4 (1.0) 2 (0.5) 1 (1.5)
Partial response 90 (22.0) 15 (3.6) 4 (6.2)
Stable disease 140 (34.1) 224 (54.5) 3 (4.6)
Progressive disease 142 (34.6) 106 (25.8) 49 (75.4)
Unable to determine 34 (8.3) 64 (15.6) 8 (12.3)
Ongoing response, n/N (%) 26/94 (27.7) 3/17 (17.6) 2/5 (40.0)
Abbreviation: CI, confidence interval.
FIGURE 2. Duration of response in all randomized patients. CI indicates confidence interval.
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of patients (grade 3 or 4, 13.8%) after the crossover 
from everolimus to nivolumab.
Throughout the study, treatment-related select AEs 
of any grade occurred among patients in the nivolumab 
arm as follows: skin, 27.8% (grade 3 or 4, 1.2%); gastro-
intestinal, 14.0% (grade 3 or 4, 2.2%); endocrine, 11.1% 
(grade 3 or 4, 1.0%); hepatic, 11.3% (grade 3 or 4, 3.0%); 
renal, 6.9% (grade 3 or 4, 1.0%); and pulmonary, 5.2% 
(grade 3 or 4, 1.5%; see Supporting Table 4; data for ever-
olimus are shown in Supporting Table 5). Tracking the 
most common organ classes of treatment-related select 
AEs over time, we found that the incidence of most events 
peaked during the initial 7 months of therapy, after which 
the incidence declined (Fig. 4B). Some select endocrine 
treatment–related AEs required management with per-
manent hormone replacement therapy (Fig. 4B). In the 
nivolumab arm, 47 of the 406 treated patients (11.6%) 
required ≥40 mg of prednisone per day (or equivalent) 
for a median duration of 3.14 weeks for the management 
of treatment-related select AEs.
FIGURE 3. TFI, duration of therapy, duration of response, and subsequent therapy for all patients with confirmed responses to (A) 
nivolumab or (B) everolimus. TFI indicates treatment-free interval.
A
B
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Quality of Life
Treatment with nivolumab was associated with rapid and 
sustained improvement in HRQOL from the baseline at 
each assessment point through week 104 per FKSI-DRS 
based on the primary analysis of CheckMate 025.5 More 
than 10 randomized patients with a baseline HRQOL 
assessment plus 1 or more postbaseline HRQOL assess-
ments had nonmissing patient-reported outcome data 
from weeks 4 through 228 and week 236 for nivolumab 
and from weeks 4 through 120 and week 132 for everoli-
mus. The average change from the baseline (defined as a 
mean change in the FKSI-DRS score ≥ 2) was improved 
at weeks 56, 68, 104, 112, 116, 124, 144, 164, and 176 
for patients in the nivolumab arm. The mean change 
from the baseline remained the same or deteriorated for 
patients in the everolimus arm (Fig. 5).
Subsequent Therapy
In total, 276 patients (67.3%) in the nivolumab arm 
and 296 patients (72.0%) in the everolimus arm 
(including those in the everolimus arm who crossed 
over to the nivolumab extension phase) received sub-
sequent systemic anticancer therapy. The median time 
from the last study drug dose to subsequent systemic 
therapy was 7.9 weeks (95% CI, 6.1-9.0 weeks) with 
nivolumab and 5.1 weeks (95% CI, 4.3-6.0 weeks) with 
everolimus. The most common subsequent systemic 
therapies in the nivolumab arm were everolimus (143 
patients [34.9%]), axitinib (137 [33.4%]), cabozan-
tinib (58 [14.1%]), and pazopanib (50 [12.2%]). In the 
everolimus arm, the most common subsequent thera-
pies were axitinib (169 patients [41.1%]), nivolumab 
(107 [26.0%], including patients who had crossed over 
to nivolumab), pazopanib (78 [19.0%]), sorafenib (45 
[10.9%]), and sunitinib (46 [11.2%]).
Among patients who crossed over to nivolumab and 
received subsequent systemic therapy, the most common 
subsequent therapies received were axitinib (37 patients 
[56.9%]), pazopanib (16 [24.6%]), cabozantinib (12 
[18.5%]), and sunitinib (14 [21.5%]).
FIGURE 4. (A) Treatment-related AEs reported in ≥10% of treated patients in either arm and (B) median time to onset and resolution 
of nivolumab-related select (immune-related) AEs of any grade. aNo patient reported a grade 3 or 4 treatment-related AE. bLess 
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DISCUSSION
The clinical benefit of nivolumab in the treatment of 
patients with aRCC after antiangiogenic therapy in 
CheckMate 025 was demonstrated with long-term fol-
low-up. The significant OS benefit with nivolumab over 
everolimus was maintained with 64 months of minimum 
follow-up, with 60-month OS probabilities for nivolumab 
and everolimus of 26% and 18%, respectively. In the pri-
mary analysis, median PFS was similar between arms4; 
however, the PFS curves separated with longer follow-up 
and favored nivolumab over everolimus. The confirmed 
ORR was higher, and more patients demonstrated an on-
going response at long-term follow-up with nivolumab 
versus everolimus. The proportion of responders who 
experienced a treatment-free interval was higher with 
nivolumab than everolimus, and a lower proportion of 
responders treated with nivolumab required subsequent 
anticancer therapy in comparison with everolimus-treated 
patients; this suggests that antitumor effects persist after 
the discontinuation of nivolumab. This pattern of long-
standing response appears to be characteristic of immuno-
therapy-based treatment in RCC and has been previously 
observed with interleukin 2 therapy and more recently in 
a long-term follow-up of the combination of nivolumab 
plus ipilimumab for previously untreated patients with 
aRCC in CheckMate 214.11-14
Few additional treatment-related AEs (including 
those leading to discontinuation) and no additional 
deaths were observed with longer follow-up in either 
arm in comparison with the primary disclosure of re-
sults from this trial.15 There was a lower incidence of 
any-grade and high-grade treatment-related AEs with 
nivolumab versus everolimus, and this was consistent 
with the primary analysis. Similarly to previous reports 
of phase 1 or 2 trials of nivolumab monotherapy,15-17 
the most common treatment-related select AEs were 
fatigue, pruritus, nausea, and diarrhea in this phase 
3 trial. Treatment-related select AEs of high grade or 
any grade were uncommon with nivolumab, and most 
select AEs were resolved and were manageable with 
established algorithms. For the first time, we report data 
on the use of corticosteroids (≥40 mg of prednisone 
daily or the equivalent) to manage treatment-related 
select AEs occurring within 30 days of the last dose. 
Relatively few patients required immune-modulating 
therapy in this setting of nivolumab monotherapy for 
the treatment of RCC. No new safety signals were ap-
parent with extended follow-up in comparison with the 
primary analysis of this phase 3 trial or previous reports 
of the early-phase studies of nivolumab monotherapy 
in aRCC.4,15-17 This study included patient-reported 
outcomes for patients treated with nivolumab versus 
FIGURE 5. Mean changes from baseline Functional Assessment of Cancer Therapy Kidney Symptom Index–Disease-Related 
Symptoms (FKSI-DRS) scores. Only time points for which data were available for 10 or more randomized patients with a baseline 
HRQOL assessment plus 1 or more postbaseline HRQOL assessments with nonmissing patient-reported outcome data per arm were 
included. Time 0 indicates the baseline. Bars show 95% confidence intervals. aThe mean change from the baseline was also clinically 
meaningful at weeks 144, 164, and 176 in the nivolumab arm. bn = 8 for week 232 and n < 10 after week 236 in the nivolumab arm; 
n = 9 for weeks 124, 128, and 136 in the everolimus arm and n < 10 otherwise after week 132. *This denotes a clinically meaningful 
improvement with nivolumab (+2) or deterioration with everolimus (–2) from the baseline (dashed lines). HRQOL indicates health-
related quality of life.
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everolimus and showed that nivolumab treatment re-
sulted in a sustained HRQOL benefit in comparison 
with everolimus; this highlights the favorable risk/ben-
efit profile of nivolumab over everolimus with extended 
follow-up.
Patients who crossed over from everolimus to 
nivolumab during the study were a highly select sub-
group of previously treated patients with a favorable 
prognosis in comparison with the overall trial popu-
lation. This subgroup of crossover patients achieved a 
higher ORR with nivolumab and longer OS and PFS 
than patients treated with everolimus who did not 
cross over to nivolumab. No new safety signals were 
observed in patients who crossed over to nivolumab 
in comparison with patients originally randomized to 
nivolumab treatment. These data suggest that patients 
with aRCC can derive clinically meaningful benefits 
from nivolumab treatment in the setting of a later line 
of treatment after antiangiogenic therapy.
Although the association of baseline risk factors 
with poor OS outcomes trended as expected in the 
univariable and multivariable analysis, many did not 
reach statistical significance for nivolumab in the lim-
ited sample size with which this analysis was performed. 
The exploratory multivariable analysis showed that the 
association of individual risk factors with OS differed 
between treatment arms, and baseline tumor PD-L1 ex-
pression and most IMDC baseline risk factors were not 
associated with worse OS outcomes with nivolumab. Yet, 
lower hemoglobin levels, a higher tumor burden (sum of 
the reference diameters of target lesions), and a shorter 
time from the diagnosis of metastatic disease to the ini-
tiation of treatment were negatively prognostic for OS 
with nivolumab. These results suggest that predictive or 
prognostic factors for OS differ for patients treated with 
immunotherapy versus targeted therapies, and improved 
prognostic models based on the underlying tumor biol-
ogy dictating the response to immunotherapy are needed 
for previously treated patients with aRCC.
The safety and efficacy of nivolumab monotherapy 
have been explored in metastatic RCC patient popula-
tions that were excluded from eligibility in our study, 
including patients with non–clear cell histology18,19 and 
asymptomatic brain metastases.20 These studies support 
the clinical benefit of nivolumab treatment in these 2 
specific patient populations, which are not represented 
in CheckMate 025.4 The immunotherapeutic land-
scape of aRCC is evolving with the first approval of the 
combination of nivolumab plus ipilimumab in the first-
line setting for patients with aRCC and intermediate 
or poor risk factors followed by other immunotherapy 
combinations.1,21-25
In summary, this extended follow-up analysis (64-
month minimum follow-up) reports the durability of 
responses and survival benefits and the greater prob-
ability of remaining progression-free with nivolumab 
versus everolimus. No new safety signals were detected 
with nivolumab or everolimus, and the previously ob-
served improvement in quality of life with nivolumab 
was sustained. To our knowledge, this 5-year analysis 
of the CheckMate 025 trial is the longest follow-up of 
a phase 3 trial of immune checkpoint inhibitor ther-
apy reported to date in previously treated patients with 
aRCC.
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